Pharmacists' role in buprenorphine management for opioid use disorder: A narrative review

被引:7
|
作者
Cleary, Jacqueline [1 ]
Engle, Amanda [1 ]
Winans, Amanda [2 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Albany, NY USA
[2] Bassett Med Ctr, Cooperstown, NY USA
来源
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | 2022年 / 5卷 / 02期
关键词
buprenorphine; collaborative care model; collaborative practice model; opioid use disorder; pharmacist; CARE;
D O I
10.1002/jac5.1579
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The continued rise in patients treated for opioid use disorder (OUD) has called for an increase in access to OUD therapies. Pharmacists, who have previously demonstrated their value in various disease states, have begun to address gaps in OUD care by facilitating buprenorphine treatment. The objective was to review current literature and characterize the pharmacists' role in buprenorphine collaborative care models for patients with OUD. PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were queried through May 2021. Studies were included if a pharmacist was part of a care model in which buprenorphine was prescribed for OUD and excluded if there was a pain management indication, a limited pharmacist role, or a survey methodology was used. Eight care models were included in this review. Key characteristics identified were (1) pharmacist role, (2) collaborating prescriber type, (3) clinic setting, (4) pharmacist practice type, and (5) outcomes. All models were located within a variety of outpatient settings. No collaborative practice model involved autonomous buprenorphine prescriptive authority by pharmacists. The majority utilized a psychiatrist as a collaborating prescriber, alongside a psychiatry-trained pharmacist. Less than half utilized pharmacists to make dosing recommendations. Outcomes evaluating treatment retention and relapse rates were most reported. Most outcomes identified across each model were either improved or unchanged by pharmacist involvement. Pharmacists are valued members of buprenorphine care teams across a variety of settings, collaborate with various clinicians, and have a positive impact on patient outcomes such as treatment retention and relapse. Few published collaborative care models exist, suggesting pharmacists may be underutilized in caring for this growing patient population. The role of the pharmacist in buprenorphine management is not currently well-defined; however, pharmacists are well prepared to take a more active role to help address the opioid crisis.
引用
收藏
页码:228 / 238
页数:11
相关论文
共 50 条
  • [21] Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review
    K. K. Adams
    M. Machnicz
    D. M. Sobieraj
    Addiction Science & Clinical Practice, 16
  • [22] Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy
    Perry, Briana N.
    Vais, Simone
    Boateng, Jeffery O.
    Jain, Mayuri
    Wachman, Elisha M.
    Saia, Kelley A.
    JOURNAL OF ADDICTION MEDICINE, 2022, 16 (06) : E389 - E394
  • [23] Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review
    Guillen, Aileen G.
    Reddy, Minal
    Saadat, Soheil
    Chakravarthy, Bharath
    TELEMEDICINE AND E-HEALTH, 2022, 28 (06) : 761 - 767
  • [24] Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data
    Hjelmstrom, Peter
    Nordbeck, Elin Banke
    Tiberg, Fredrik
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2020, 46 (01) : 1 - 7
  • [25] Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review
    Adams, K. K.
    Machnicz, M.
    Sobieraj, D. M.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2021, 16 (01)
  • [26] Buprenorphine for Chronic Pain Management: a Narrative Review
    Peter D. Vu
    Vishal Bansal
    Ahish Chitneni
    Christopher L. Robinson
    Omar Viswanath
    Ivan Urits
    Alan D. Kaye
    Anvinh Nguyen
    Ranganathan Govindaraj
    Grant H. Chen
    Jamal Hasoon
    Current Pain and Headache Reports, 2023, 27 : 811 - 820
  • [27] Buprenorphine for Chronic Pain Management: a Narrative Review
    Vu, Peter D.
    Bansal, Vishal
    Chitneni, Ahish
    Robinson, Christopher L.
    Viswanath, Omar
    Urits, Ivan
    Kaye, Alan D.
    Nguyen, Anvinh
    Govindaraj, Ranganathan
    Chen, Grant H.
    Hasoon, Jamal
    CURRENT PAIN AND HEADACHE REPORTS, 2023, 27 (12) : 811 - 820
  • [28] Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study
    Mullins, Nathan
    Galvin, Shelley L.
    Ramage, Melinda
    Gannon, Marie
    Lorenz, Kathleen
    Sager, Brent
    Coulson, Carol C.
    JOURNAL OF ADDICTION MEDICINE, 2020, 14 (03) : 185 - 192
  • [29] Association Between Length of Buprenorphine or Methadone Use and Nonprescribed Opioid Use Among Individuals with Opioid Use Disorder: A Cohort Study
    Jiang, Xinyi
    Guy Jr, Gery P.
    Dever, Jill A.
    Richardson, John S.
    Dunlap, Laura J.
    Turcios, Didier
    Wolicki, Sara Beth
    Edlund, Mark J.
    Losby, Jan L.
    SUBSTANCE USE & ADDICTION JOURNAL, 2025, 46 (02): : 266 - 279
  • [30] Buprenorphine-naloxone versus buprenorphine for opioid use disorder during pregnancy: A systematic review and meta-analysis
    de Lima, Fernanda Ribeiro
    Molino, Gabriela Oliveira Goncalves
    Ruelas, Mariano Gallo
    Barbosa, Eduardo Cerchi
    da Silva, Pedro Henrique Costa Matos
    Guimaraes, Felipe Bandeira de Melo
    Petrucci, Arthur Bezerra Cavalcanti
    da Silva, Giovanna Hanike Santos
    Sbardelotto, Angelo Eduardo Espindola
    Lanca, Saulo Bernardo
    Garbacka, Alicja
    DRUG AND ALCOHOL DEPENDENCE, 2025, 271